“A company that feels it has to define the purpose of Hellmann’s mayonnaise has in our view clearly lost the plot,” sniped investment firm Fundsmith last week, in a “withering criticism” of Unilever’s woke ideology and poorly performing shares, said The Economist. CEO Alan Jope had the perfect retort. The conglomerate has been quietly plotting a blockbuster £50bn mega-merger with GlaxoSmithKline’s consumer healthcare arm to create an all-British consumer goods champion, with brands ranging from Marmite, Pot Noodle and Dove (Unilever), to Sensodyne, Panadol and Tums (GSK). Forget allegations of navel-gazing. How’s that for action?
GSK, which has thrice turned down Unilever’s overtures, isn’t keen, said Ben Marlow in The Daily Telegraph. CEO Emma Walmsley wants to list the consumer arm (currently part-owned by Pfizer) instead. Neither is the market keen: it sent Unilever’s shares 7% south. “This is a very bad idea,” said BNP Paribas. “Please don’t,” added RBC Capital Markets, which reckons Unilever’s attempt at empire-building is “to compensate for, and distract attention from” its problems. History certainly suggests that giant deals like this tend to “destroy value”.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
Join more than 350,000 subscribers and keep yourself informed with a selection of The Week’s most interesting, enlightening and entertaining stories - plus daily puzzles.
Join more than 350,000 subscribers and keep yourself informed with a selection of The Week’s most interesting, enlightening and entertaining stories - plus daily puzzles.